Mounjaro vs Ozempic
Mounjaro is tirzepatide. Ozempic is semaglutide. Both are once-weekly injections licensed in the United States for type 2 diabetes, made by different companies — Mounjaro by Eli Lilly, Ozempic by Novo Nordisk.
Because both are widely discussed in the context of weight, it is worth being precise about what these two specific brands are actually licensed for, and where the weight-management conversation properly belongs.
- MounjaroTirzepatide
- OzempicSemaglutide
- Both licensed forType 2 diabetes
- RouteWeekly injection
What each brand is licensed for
This is the part that gets muddled most often. Mounjaro and Ozempic are both licensed in the US for type 2 diabetes. Neither is the weight-management brand of its molecule — those are Zepbound and Wegovy respectively.
| Brand | Molecule | US indication | Maker |
|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes | Eli Lilly |
| Ozempic | Semaglutide | Type 2 diabetes | Novo Nordisk |
| Zepbound | Tirzepatide | Chronic weight management | Eli Lilly |
| Wegovy | Semaglutide | Chronic weight management | Novo Nordisk |
If your goal is weight management, the relevant comparison is usually Wegovy against Zepbound rather than these two. Prescribing outside a licensed indication happens, but it is a decision a clinician makes explicitly, and it changes how insurers respond.
How the two differ mechanically
Ozempic's semaglutide engages one incretin pathway, GLP-1. Mounjaro's tirzepatide engages that one plus GIP. That is the structural difference, and it is the same difference you would find comparing Wegovy to Zepbound, because the underlying molecules are the same.
Both are supplied as once-weekly subcutaneous injections, and both are started low and adjusted upward over time under supervision. What that schedule looks like is determined by a licensed provider.
Coverage and cost factors
We publish no price here. For a diabetes-labeled product the decisive question is almost always formulary placement: whether your specific plan lists that brand, at what tier, and whether it requires you to try something else first.
- Formulary tier and prior-authorisation requirements, which differ between the two brands even within one insurer.
- Step therapy — some plans require a trial of an older medicine before covering either.
- Manufacturer savings programs, typically conditional on commercial insurance.
- Supply. Both brands have seen constrained periods, and a pharmacy that can fill one may not be able to fill the other.
What to ask
Ask which of the two your plan actually covers before you get attached to either. Ask what the prior-authorisation criteria are, and whether your record already satisfies them. And ask what the plan does if supply tightens — being switched mid-course is disruptive and worth planning for.
Two separate approvals, two different molecules
These are not two brands of one medicine. Each holds its own application in FDA's Drugs@FDA database: Ozempic is a semaglutide product under application 209637, and Mounjaro is a tirzepatide product under application 215866. Separate applications mean separate review records, separate labels and separate licensed indications.
That matters when setting them side by side, because an approval attaches to a product and a population rather than to a molecule in general. The same active ingredient can appear in more than one approved product under different brand names and different licensed indications — tirzepatide does exactly that, with a second approval for chronic weight management under a different brand.
What none of this settles is which one suits any individual. That turns on the condition being managed, what else a person is taking, and clinical judgement about tolerability — questions for a licensed prescriber holding the whole picture, not for a comparison page. What a page like this can do is make the regulatory footing clear enough that you know which questions to ask.
Provenance
Sources
- FDA Drugs@FDA — OZEMPIC (semaglutide) injection, NDA 209637 — retrieved 2026-08-13
- FDA Drugs@FDA — MOUNJARO (tirzepatide) injection, NDA 215866 — retrieved 2026-08-13
- FDA — FDA Approves New Medication for Chronic Weight Management (Zepbound, tirzepatide) — retrieved 2026-08-13
Questions
Mounjaro vs Ozempic: common questions
- Is Mounjaro approved for weight loss?
- In the United States, Mounjaro is licensed for type 2 diabetes. The same molecule is licensed for chronic weight management under the brand Zepbound.
- Is Ozempic the same as Wegovy?
- Both contain semaglutide, but they are separate products with separate licensed indications and separate coverage. They are not interchangeable at the pharmacy counter.
- Which is stronger?
- They are different molecules engaging different combinations of receptors, so "stronger" is not a meaningful comparison. What matters clinically is which is appropriate for you, and that is a prescriber's call.
- Can I get either through telehealth?
- Prescribing practices vary by provider and state. Both are ordinary prescription medicines rather than controlled substances, so the telehealth rules that constrain some other treatments do not apply in the same way.
Talk to a licensed prescriber about which one fits you
We do not prescribe, and we do not pick for you. We point you at licensed providers who can assess your situation, check your coverage, and tell you what each option would actually mean for you.
Find a licensed prescriberMedical disclaimer
TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.
We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.
Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.